- July 5, 2018
- Posted by: PharmaScroll
NEUPRO now approved in China for the treatment of the signs and symptoms of early-stage idiopathic Parkinson’s Disease as monotherapy (i.e. without levodopa) or in combination with levodopa
Belgium-based global bio-pharmaceutical company UCB announced it has received an Import Drug License (IDL) from the China Food and Drug Administration (CFDA), creating a pathway to make the company’s 24-hour continuous delivery transdermal rotigotine patch NEUPRO® available to patients in China.
Parkinson’s disease (PD) is a chronic, degenerative neurological disease with an estimated prevalence of 1.7% in China in people aged 65 years and older. Estimates suggest that around 3 million people in China are affected by the condition.
With this IDL, NEUPRO is now indicated in China for the treatment of the signs and symptoms of early-stage idiopathic Parkinson’s Disease as monotherapy (i.e. without levodopa) or in combination with levodopa, i.e. over the course of the disease, through to late stages when the effect of levodopa wears off or becomes inconsistent and fluctuations of the therapeutic effect occur (end of dose or ‘on-off’ fluctuations).
NEUPRO is designed to support and improve individual patient treatment experiences for people living with Parkinson’s Disease. The product’s unique transdermal patch formulation is administered once daily, providing a continuous release of rotigotine over a 24-hour period.
“The availability of NEUPRO® in China is testament to UCB fulfilling our commitment to provide additional value to patients around the world.” said Jeff Wren, Executive Vice-President, Head of UCB’s Neurology Patient Value Unit. “We know the significant impact Parkinson’s can have on the lives of patients and their family members, and how important it is to effectively manage symptoms to allow patients to keep their independence and maintain their quality of life. With the approval of NEUPRO® in China, we are very excited that we will be able to make this medicine available to the millions of people affected by Parkinson’s Disease in the country, providing them with a convenient treatment option to help them to manage their condition.”
As a result of the IDL, UCB will now progress with NEUPRO launch planning, to ensure patients in China with Parkinson’s are able to benefit from this approval as quickly as possible.
Pharmascroll is a diligent business consulting and market research firm focused solely towards pharmaceutical markets. The company consults and researches in majorly chronic disease indications prevalent across the globe. The research conducted by Pharmascroll analysts is targeted to provide analytical and logical answers to the key business questions of the pharmaceutical and medical insights teams and to make better informed business decisions with the detailed relevant information available.
To read more news about Parkinson’s disease indication, visit https://pharmascroll.com/news-category/parkinsons/
News Source: UCB Pharmaceuticals Website